COMPASS THERAPEUTICS, INC. Research and Development Expense
COMPASS THERAPEUTICS, INC. (CMPX) reported Research and Development Expense of $13.39 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-05
- COMPASS THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $13.39M, a 2.57% increase year-over-year.
- COMPASS THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $13.67M, a 4.86% increase year-over-year.
- COMPASS THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $12.83M, a 48.93% increase year-over-year.
- COMPASS THERAPEUTICS, INC. research and development expense for the quarter ending 2025-06-30 was $16.41M, a 46.90% increase year-over-year.
- COMPASS THERAPEUTICS, INC. research and development expense for fiscal 2025 was $55.97M, a 32.18% increase from fiscal 2024.
- COMPASS THERAPEUTICS, INC. research and development expense for fiscal 2024 was $42.34M, a 11.08% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. research and development expense for fiscal 2023 was $38.12M.
- COMPASS THERAPEUTICS, INC. research and development expense for fiscal 2020 was $14.90M, a 33.61% decline from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $13.39M 10-Q · filed 2026-05-05 | $27.06M derived: sum of 2 quarters · filed 2026-05-05 | $39.89M derived: sum of 3 quarters · filed 2026-05-05 | $56.30M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $13.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $26.50M derived: sum of 2 quarters · filed 2026-03-05 | $42.91M derived: sum of 3 quarters · filed 2026-03-05 | $55.97M 10-K · filed 2026-03-05 |
| 2025-09-30 | $12.83M 10-Q · filed 2025-11-05 | $29.24M derived: sum of 2 quarters · filed 2025-11-05 | $42.30M 10-Q · filed 2025-11-05 | $55.33M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $16.41M 10-Q · filed 2025-08-11 | $29.48M 10-Q · filed 2025-08-11 | $42.51M derived: sum of 3 quarters · filed 2026-05-05 | $51.12M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $13.05M 10-Q · filed 2026-05-05 | $26.09M derived: sum of 2 quarters · filed 2026-05-05 | $34.70M derived: sum of 3 quarters · filed 2026-05-05 | $45.88M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $13.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $21.65M derived: sum of 2 quarters · filed 2026-03-05 | $32.82M derived: sum of 3 quarters · filed 2026-03-05 | $42.34M 10-K · filed 2026-03-05 |
| 2024-09-30 | $8.61M 10-Q · filed 2025-11-05 | $19.79M derived: sum of 2 quarters · filed 2025-11-05 | $29.30M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $11.17M 10-Q · filed 2025-08-11 | $20.70M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $9.52M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $38.12M 10-K · filed 2025-02-27 | |||
| 2021-03-31 | $4.70M 10-Q · filed 2021-04-30 | $9.11M derived: sum of 2 quarters · filed 2021-04-30 | $12.78M derived: sum of 3 quarters · filed 2021-04-30 | $15.77M derived: sum of 4 quarters · filed 2021-04-30 |
| 2020-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $8.08M derived: sum of 2 quarters · filed 2021-03-05 | $11.06M derived: sum of 3 quarters · filed 2021-03-05 | $14.90M 10-K · filed 2021-03-05 |
| 2020-09-30 | $3.67M 10-Q · filed 2020-11-09 | $6.66M derived: sum of 2 quarters · filed 2020-11-09 | $10.50M 10-Q · filed 2020-11-09 | $13.53M derived: sum of 4 quarters · filed 2021-04-30 |
| 2020-06-30 | $2.98M 10-Q · filed 2020-08-13 | $6.56M 10-Q · filed 2020-08-13 | $9.86M derived: sum of 3 quarters · filed 2021-04-30 | $15.84M derived: sum of 4 quarters · filed 2021-04-30 |
| 2020-03-31 | $3.57M 10-Q · filed 2021-04-30 | $6.87M derived: sum of 2 quarters · filed 2021-04-30 | $12.85M derived: sum of 3 quarters · filed 2021-04-30 | $18.24M derived: sum of 4 quarters · filed 2021-04-30 |
| 2019-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $9.28M derived: sum of 2 quarters · filed 2021-03-05 | $14.67M derived: sum of 3 quarters · filed 2021-03-05 | $22.45M 10-K · filed 2021-03-05 |
| 2019-09-30 | $5.98M 10-Q · filed 2020-11-09 | $11.37M derived: sum of 2 quarters · filed 2020-11-09 | $19.15M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $5.39M 10-Q · filed 2020-08-13 | $12.63M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |